Drugs / ICP-105
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03642834 | Sep 2018 → Dec 2020 | cancer | Beijing InnoCare Pharma Tech Co., Ltd. | Completed | No outcome recorded |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ICP-105 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03642834 ↗ |